Heart Failure Post-Infarction: Relevance of the Problem
Heart failure (HF) is one of the most frequent and serious complications of acute myocardial infarction (MI), significantly increasing mortality risk and the demand for medical resources [3, 4, 7]. Despite significant advances in the diagnosis and treatment of MI over recent decades, the development of HF and/or left ventricular systolic dysfunction (LVSD) remains a widespread problem [4]. Patients with LVSD post-MI are at an even higher risk of recurrent ischemic events, worsening HF, and sudden death [7].
A key objective in treating such patients is preventing or reversing left ventricular remodeling, which develops after an infarction and is the primary cause of HF progression [4, 7]. Modern approaches focus on aggressive medical strategies capable of saving lives and preventing disability [4].
The Four Pillars of Therapy: The Foundation of Heart Failure Treatment
In the treatment of heart failure with reduced ejection fraction (HFrEF), the so-called "four pillars" or "fantastic four" of medications have become firmly established. These include beta-blockers, mineralocorticoid receptor antagonists (MRAs), angiotensin receptor-neprilysin inhibitors (ARNIs), and sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) [3]. Although their efficacy is well-proven for HFrEF, their role in preventing HF immediately following an acute MI continues to be studied [3].
Beta-Blockers
Beta-blockers have long been the standard of care post-MI, especially in the era prior to the widespread use of revascularization when HF was a frequent occurrence. Large randomized trials in the mid-1980s showed that beta-blockers significantly improve survival in patients with MI both in-hospital and long-term [2].
Bisoprolol, for instance, is widely used to treat moderate to severe chronic stable HF, coronary artery disease, and hypertension. A study involving patients with MI and heart failure showed that bisoprolol combined with standard care significantly improves heart function, reduces homocysteine (Hcy) and C-reactive protein (CRP) levels, without causing serious adverse reactions. The overall therapeutic efficacy was significantly higher in the group receiving bisoprolol [1]. Carvedilol has also shown benefits in large clinical trials [4].
However, in the modern era of rapid myocardial reperfusion—which substantially reduces infarct size and lowers the incidence of HF—the question of lifelong beta-blocker use after an uncomplicated MI has become a subject of debate. Modern large registries have not provided sufficient evidence to support long-term beta-blocker therapy in such patients, which, alongside frequent side effects and adherence issues, has led to a revision of guidelines [2].
Mineralocorticoid Receptor Antagonists (MRAs)
Drugs in this group, such as eplerenone, have also demonstrated significant benefits in large clinical trials, particularly in the context of preventing left ventricular remodeling post-MI [4].
ARNIs and SGLT2 Inhibitors
Angiotensin receptor-neprilysin inhibitors (ARNIs) and sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) are relatively new classes of drugs that have revolutionized HFrEF treatment. Their effects in preventing HF after acute MI are actively being studied, and they are expected to occupy an important place in treatment protocols [3].
Additional and Prominent Emerging Treatments
Beyond the main drug classes, there are other therapeutic approaches that improve patient prognosis and quality of life:
- Levosimendan: This is a novel calcium-sensitizing agent which, according to the RUSSLAN study, can be safely used in patients with post-infarction HF in the absence of severe hypotension. It has shown improvements in symptoms and survival, making it unique among intravenous inotropic agents if these results are confirmed [5].
- Antithrombotic and Cholesterol-Lowering Drugs: Randomized clinical trials have shown that effective antithrombotic and cholesterol-lowering agents also reduce the risk of cardiovascular events in post-MI patients, especially those at very high risk, such as those with LVSD [7].
Preventing Remodeling and Improving Prognosis
The primary goal of pharmacological therapy post-MI, particularly in patients with LVSD, is to prevent post-infarction myocardial remodeling. Neurohormonal antagonists play a key role in this process, significantly improving short- and long-term outcomes, including reductions in mortality, recurrent infarctions, and worsening HF [7]. Aggressive medical strategies aimed at preventing or reversing infarction-related left ventricular remodeling remain the most effective method for saving lives and preventing disability [4].
Challenges and Future Directions
Despite significant achievements, cardiovascular diseases (CVDs) remain the leading cause of death worldwide, and post-MI HF remains a serious problem [8]. Oxidative stress and inflammation critically contribute to the development of atherosclerosis, cardiac remodeling, and myocardial infarction [8]. Researchers have identified numerous potential drug targets in preclinical studies; however, few new agents have been approved for clinical use, indicating the need for further research and the development of innovative therapeutic strategies [8].
Sources
- The Efficacy and Safety of Bisoprolol in the Treatment of Myocardial Infarction with Cardiac Insufficiency.
- Do Patients need Lifelong β-Blockers after an Uncomplicated Myocardial Infarction?
- Pharmacological and Device-Based Intervention for Preventing Heart Failure After Acute Myocardial Infarction - A Clinical Review.
- Trends and treatment of heart failure developing after acute myocardial infarction.
- Heart failure update.
- Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence.
- Recent updates on novel therapeutic targets of cardiovascular diseases.
The information provided in this article is for reference purposes only and cannot replace professional medical advice. Always consult a specialist before beginning any treatment or modifying current therapy.